Literature DB >> 29409534

The implausible "in vivo" role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota.

Gilda Tachedjian1,2,3,4, Deirdre E O'Hanlon5,6, Jacques Ravel7,8.   

Abstract

In the cervicovaginal environment, the production of hydrogen peroxide (H2O2) by vaginal Lactobacillus spp. is often mentioned as a critical factor to the in vivo vaginal microbiota antimicrobial properties. We present several lines of evidence that support the implausibility of H2O2 as an "in vivo" contributor to the cervicovaginal milieu antimicrobial properties. An alternative explanation is proposed, supported by previous reports ascribing protective and antimicrobial properties to other factors produced by Lactobacillus spp. capable of generating H2O2. Under this proposal, lactic acid rather than H2O2 plays an important role in the antimicrobial properties of protective vaginal Lactobacillus spp. We hope this commentary will help future research focus on more plausible mechanisms by which vaginal Lactobacillus spp. exert their antimicrobial and beneficial properties, and which have in vivo and translational relevance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29409534      PMCID: PMC5801833          DOI: 10.1186/s40168-018-0418-3

Source DB:  PubMed          Journal:  Microbiome        ISSN: 2049-2618            Impact factor:   14.650


Main text

In 1892, Albert Doderlein first described the presence of Gram-positive bacilli in the vagina of healthy reproductive-age women with low vaginal pH [1]. He considered the anti-staphylococci activities of the vaginal bacilli and the bactericidal action of the vaginal secretions to be due to the lactic acid produced by the bacilli [2]. His findings and those of others led to the proposal that vaginal acidification by lactic acid producing Lactobacillus spp. is the primary mechanism by which these bacteria contribute to the protection against reproductive tract pathogens [1, 2]. In addition to releasing organic acid metabolites (e.g., lactic acid) known to provide antimicrobial and immunomodulatory properties, Lactobacillus spp. can outcompete other bacteria at the epithelial mucosa as well as releasing bacteriocins, surfactants, antimicrobial proteins, or peptides [3-5]. In the 1990s, Lactobacillus species that produced H2O2 gained favour as being antimicrobial and synonymous with the presence of an optimal protective vaginal microbiota in reproductive-age women [6]. The protective role ascribed to H2O2 largely stems from epidemiological studies linking the presence in the vagina of H2O2-producing Lactobacillus spp. with a decreased risk for bacterial vaginosis (BV) [6-9], sexually transmitted infections [10, 11], as well as adverse birth outcomes [12], compared to women harboring non-H2O2-producing vaginal Lactobacillus. Unfortunately, these epidemiological observations were interpreted into the now widely accepted statement that “in vivo, Lactobacillus spp. exerts its antimicrobial properties through the production of H2O2”. While we do not dispute these epidemiological studies, the notion that in vivo H2O2 production by vaginal Lactobacillus spp. is an important factor contributing to the antimicrobial properties of these species is highly unlikely in the context of physiological conditions present in the lower female reproductive tract (FRT). In this commentary, several lines of evidence are presented that support the implausibility of “in vivo” H2O2 as an antimicrobial factor in the cervicovaginal environment. An alternative explanation is proposed, supported by previous reports ascribing protective and antimicrobial properties to other factors produced by Lactobacillus spp. capable of generating H2O2. Under this proposal, lactic acid rather than H2O2 plays an important role in the antimicrobial properties of protective vaginal Lactobacillus spp. A fact that is not disputed is that in any microbial system, no matter the mechanism (pyruvate oxidase, lactate oxidase or NADH oxidase or NADH-dependent flavin mononucleotide reductase) [13], O2 is required to produce H2O2, and in large amounts to achieve H2O2 concentrations necessary to have antimicrobial activity in the vaginal environment [14-16]. Thus, a major question is how much oxygen is present to support this reaction in the vagina. The cervicovaginal environment is microaerobic (hypoxic) [17]. The mean cervicovaginal O2 levels range from 15 to 35 mmHg (2%), which is much lower than atmospheric levels of 160 mmHg (21%) [17-19]. Conversely, the cervicovaginal CO2 partial pressure ranges from 35 to 55 mmHg (or 5%), which is considerably higher than atmospheric levels (i.e., 5 mmHg, 0.04%) [17-19]. Only transient increases in O2, that rarely achieve atmospheric levels, have been reported upon or after tampon or diaphragm insertion, sexual arousal [17, 18, 20, 21], and probably sexual intercourse. Vaginal Lactobacillus spp., like most Lactobacillus spp., are aerotolerant anaerobes and some do produce H2O2 when propagated under aerobic conditions, such as aeration by flask shaking [14, 15]. Conversely, lactic acid is predominately produced and at high concentrations under hypoxic conditions [19, 22]. Consistent with these in vitro observations and the low vaginal O2 levels measured in vivo, H2O2-producing vaginal Lactobacillus spp. have been shown to make little or no H2O2 in the context of the hypoxic cervicovaginal environment [16, 23]. The reported production of H2O2 by vaginal Lactobacillus spp. is measured using artificial in vitro conditions that do not recapitulate the hypoxic cervicovaginal environment [6, 14]. Consistent with this observation, the literature assigning an antimicrobial role for H2O2 describe experiments where Lactobacillus isolates are cultured under aerobic conditions to facilitate production and detection of H2O2 [6, 13–15, 24–26] (Table 1). Antimicrobial activity of H2O2 is observed in vitro in protein-free salt solutions, conditions that are not consistent with those in the cervicovaginal environment and an in vivo antimicrobial role for H2O2. Supporting this conclusion is the finding that H2O2 is inactivated by the reducing capabilities of cervicovaginal fluid (CVF) and semen [16, 23]. H2O2 measured in fully aerobic CVF is only 23 ± 5 μM [16]; however, CVF and semen completely reduce 1 mM and 10 mM added H2O2, respectively [16]. The addition of as little as 1% CVF supernatant completely abolishes the pathogen-inactivation by aerobically grown H2O2-producing Lactobacillus spp. [16] demonstrated by Klebanoff et al. [6]. In in vitro assays, physiological concentrations of H2O2 (< 100 μM) found in vaginal fluids, even when potentiated with myeloperoxidase, fail to inactivate bacterial vaginosis associated microbes, as well as bacterial (Neisseria gonorrhoeae) and viral (HSV-2) pathogens [16, 23]. Supra-physiological levels (10 mM) of H2O2 inactivate only one of 17 BV-associated bacterial species tested while completely inactivating four major vaginal Lactobacillus spp., L. crispatus, L. gasseri, L. jensenii, and L. iners [23]. These findings do not support an antimicrobial role for H2O2 in the cervicovaginal environment; however, the association between H2O2-producing strains of Lactobacillus spp. and favorable reproductive and urogenital outcomes may represent an in vitro marker for vaginal strains with beneficial properties. We put forth that other functions associated with these isolates capable of producing H2O2 in vitro must be responsible for their beneficial properties [3, 14, 24, 27]. In support of this proposal are issues with in vitro measurement of H2O2 production, which can be affected by growth kinetics. As such, a third of non-H2O2-producing strains were shown to ‘convert’ to H2O2 producers when the nutritional medium was reformulated [25] and in another study, 44% of non-H2O2-producing strains became producers when the time allowed for H2O2 production was increased from 30 to 60 min [12], vividly demonstrating that the difference is one of rate rather than absolute ability. Consistent with these findings, and the hypothesis that H2O2 is preferentially produced through NADH-dependent flavin mono-nucleotide reductase in lactic acid bacteria [13, 28, 29], an analysis of 125 L. iners genomes assembled from metagenomics datasets, showed that all genomes carry both genes found responsible for H2O2 production in L. johnsonii [13] and other members of the L. acidophilus group (data not shown). These finding severely weaken the association between production of H2O2 by vaginal Lactobacillus species and protection against BV, STI, and other adverse outcomes.
Table 1

Concentrations of hydrogen peroxide and lactic acid produced by Lactobacillus spp. under different conditions and concentrations necessary to inactivate HIV and BV-associated bacteria

ConditionsH2O2 [mM]Lactic acid [mM]
Culture medium under hypoxic conditionsUndetectable[46]160–250[22, 47]
Aerated culture medium3.34–4.39[46]45[22]
Lactobacillus-dominated CVF under hypoxic conditionsUndetectable[16]110[23]
Aerated Lactobacillus-dominated CVF0.023[16]63[23]
Inactivation of HIV in culture medium5[48]33[32]
Inactivation of BV-associated bacteria in culture medium10[23]55–110[23]
Inactivation of HIV in the presence of CVFUndetermined33–110[32]
Inactivation of BV-associated bacteria in the presence of CVF> 1000[23]55–110[23]
Inactivation of Lactobacillus in culture medium> 1000[23]> 1000[23]
Concentrations of hydrogen peroxide and lactic acid produced by Lactobacillus spp. under different conditions and concentrations necessary to inactivate HIV and BV-associated bacteria Vaginal Lactobacillus spp. produces lactic acid through the fermentation of polysaccharides, including glucose, under hypoxic conditions [30, 31]. In women of reproductive-age, harboring Lactobacillus-dominated vaginal microbiota, measurement of the average concentration of lactic acid in cervicovaginal fluid (CVF) under hypoxic conditions is 1.0 ± 0.2% (w/v), a concentration associated with a low pH between 3.5 and 4.5 [19] (Table 1). The strong inverse correlation between pH and lactic acid levels indicates that lactic acid is the main acidifier in the lower FRT [19]. Lactic acid has been shown to have antimicrobial activity [32, 33], as well as anti-inflammatory properties on cervicovaginal epithelial cells, which together support a role in lowering the risk of sexually transmitted infection acquisition and transmission [34, 35]. In vitro and at physiological concentrations (55–111 mM) and pH (4.5), lactic acid inactivates 17 different BV-associated bacteria, while not affecting the viability of four vaginal Lactobacillus spp. [23]. Under in vitro anaerobic conditions, lactic acid produced by L. crispatus and L. gasseri, but not H2O2, was shown to inactivate Neisseria gonorrhoeae [36], Chlamydia trachomatis [22, 37] as well as Escherichia coli [38]. Lactic acid produced by L. crispatus inhibits N. gonorrhoeae and Gardnerella vaginalis as demonstrated in a porcine vaginal mucosa explant model [39]. Interestingly, Antonio et al. found that 94, 95, and 70% of L. crispatus, L. jensenii and L. gasseri isolates, respectively, but only 9% of L. iners strains produce H2O2 in vitro [40]. Notably, the D-isomer of lactic acid is exclusively produced by L. crispatus, L. jensenii and L. gasseri, and not L. iners [41, 42], and while not extensively tested, has been shown to be associated with immobilisation of HIV-1 in mucus [43], as well as being implicated in preventing vaginal bacteria traversing the cervix to initiate upper genital tract infections [41]. Thus, the lack of H2O2-production may represent less beneficial strains of Lactobacillus spp. that do not produce high quantities of lactic acid and thus fail to acidify the vagina to low pH [29, 41] or lack the ability to produce D-lactic acid, which appears to be an essential isomer. Further, Tomás et al. [44] found that strains of vaginal Lactobacillus species producing H2O2 in vitro also produced significantly more lactic acid than non-H2O2-producing strains. Lastly, slow growth or metabolic rates might limit the competitiveness of some Lactobacillus spp. leading to lack of dominance when faced with intrinsic (e.g., menses) and extrinsic (e.g., sex) disturbances, thus frequently transitioning to BV-like microbiota comprising a wide array of strict and facultative anaerobes [45] and should also be considered.

Conclusion

The scientific literature does not support an in vivo antimicrobial role for H2O2 produced by vaginal Lactobacillus spp. The perpetuation of this concept lacks scientific justification. Definitive clarification of the lack of in vivo antimicrobial role for H2O2 is critical to focus on more plausible mechanisms by which vaginal Lactobacillus spp. exert their antimicrobial and beneficial properties, including that of lactic acid. This goal could be achieved by examining, but not limited to, the following: In vitro studies examining the antimicrobial role of Lactobacillus spp. metabolites or other factors could consider—and ideally recapitulate—the conditions generally prevailing in vivo, e.g., hypoxia and high antioxidant capacity among others. The direct antimicrobial activity of any factor, whether endogenous products of Lactobacillus spp. or exogenous formulation, could be confirmed in the presence of CVF. Epidemiological studies associating vaginal microbiota and reproductive health outcomes could incorporate quantification of putative antimicrobial factors or activities of Lactobacillus spp. in ex vivo CVF samples in prospective study designs. A shift of focus on mechanisms with translational relevance is key for the evidence-based selection of Lactobacillus spp. or Lactobacillus metabolites, and other factors, in efforts to develop and test novel biotherapeutics for the female reproductive tract.
  45 in total

1.  Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source.

Authors:  E R Boskey; R A Cone; K J Whaley; T R Moench
Journal:  Hum Reprod       Date:  2001-09       Impact factor: 6.918

2.  H(2)O(2) production in species of the Lactobacillus acidophilus group: a central role for a novel NADH-dependent flavin reductase.

Authors:  Rosanne Hertzberger; Jos Arents; Henk L Dekker; R David Pridmore; Christof Gysler; Michiel Kleerebezem; M Joost Teixeira de Mattos
Journal:  Appl Environ Microbiol       Date:  2014-01-31       Impact factor: 4.792

3.  A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology.

Authors:  Thomas L Cherpes; Sharon L Hillier; Leslie A Meyn; James L Busch; Marijane A Krohn
Journal:  Sex Transm Dis       Date:  2008-01       Impact factor: 2.830

4.  Optimization of media for detection of hydrogen peroxide production by Lactobacillus species.

Authors:  L K Rabe; S L Hillier
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

5.  The normal vaginal flora, H2O2-producing lactobacilli, and bacterial vaginosis in pregnant women.

Authors:  S L Hillier; M A Krohn; L K Rabe; S J Klebanoff; D A Eschenbach
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

6.  Hydrogen Peroxide-Producing Lactobacilli Are Associated With Lower Levels of Vaginal Interleukin-1β, Independent of Bacterial Vaginosis.

Authors:  Caroline Mitchell; David Fredricks; Kathy Agnew; Jane Hitti
Journal:  Sex Transm Dis       Date:  2015-07       Impact factor: 2.830

7.  The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth.

Authors:  Michelle A Graver; Jeremy J Wade
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-02-17       Impact factor: 3.944

8.  In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.

Authors:  Deirdre E O'Hanlon; Thomas R Moench; Richard A Cone
Journal:  BMC Infect Dis       Date:  2011-07-19       Impact factor: 3.090

9.  Lactobacillus crispatus inhibits growth of Gardnerella vaginalis and Neisseria gonorrhoeae on a porcine vaginal mucosa model.

Authors:  Laura M Breshears; Vonetta L Edwards; Jacques Ravel; Marnie L Peterson
Journal:  BMC Microbiol       Date:  2015-12-09       Impact factor: 3.605

10.  Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2.

Authors:  Zheng Gong; Yesmin Luna; Ping Yu; Huizhou Fan
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

View more
  29 in total

Review 1.  The microbiome and gynaecological cancer development, prevention and therapy.

Authors:  Paweł Łaniewski; Zehra Esra Ilhan; Melissa M Herbst-Kralovetz
Journal:  Nat Rev Urol       Date:  2020-02-18       Impact factor: 14.432

Review 2.  Host and Microbiome Interplay Shapes the Vaginal Microenvironment.

Authors:  Myoung Seung Kwon; Heung Kyu Lee
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

3.  Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.

Authors:  Irina A Zalenskaya; Neelima Chandra; Nazita Yousefieh; Xi Fang; Oluwatosin E Adedipe; Suzanne S Jackson; Sharon M Anderson; Christine K Mauck; Jill L Schwartz; Andrea R Thurman; Gustavo F Doncel
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

4.  Mucosal Immunity and HIV Acquisition in Women.

Authors:  Laura Moreno de Lara; Ragav S Parthasarathy; Marta Rodriguez-Garcia
Journal:  Curr Opin Physiol       Date:  2020-08-18

5.  Cultivable vaginal Lactobacillus is not associated with fecundability in Kenyan women attempting to conceive.

Authors:  Erica M Lokken; Clayton Jisuvei; James P Hughes; Kishor Mandaliya; Lisa E Manhart; Khamis Mwinyikai; Charles H Muller; Walter Jaoko; John Kinuthia; R Scott McClelland
Journal:  Fertil Steril       Date:  2022-01-17       Impact factor: 7.329

Review 6.  The impact of the female genital tract microbiome in women health and reproduction: a review.

Authors:  Paula Punzón-Jiménez; Elena Labarta
Journal:  J Assist Reprod Genet       Date:  2021-06-10       Impact factor: 3.357

Review 7.  HIV Pathogenesis in the Human Female Reproductive Tract.

Authors:  Marta Rodriguez-Garcia; Kaleigh Connors; Mimi Ghosh
Journal:  Curr HIV/AIDS Rep       Date:  2021-03-15       Impact factor: 5.495

8.  Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid.

Authors:  David Tyssen; Ying-Ying Wang; Joshua A Hayward; Paul A Agius; Kevin DeLong; Muriel Aldunate; Jacques Ravel; Thomas R Moench; Richard A Cone; Gilda Tachedjian
Journal:  mSphere       Date:  2018-07-05       Impact factor: 4.389

9.  The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission.

Authors:  Lyle R McKinnon; Sharon L Achilles; Catriona S Bradshaw; Adam Burgener; Tania Crucitti; David N Fredricks; Heather B Jaspan; Rupert Kaul; Charu Kaushic; Nichole Klatt; Douglas S Kwon; Jeanne M Marrazzo; Lindi Masson; R Scott McClelland; Jacques Ravel; Janneke H H M van de Wijgert; Lenka A Vodstrcil; Gilda Tachedjian
Journal:  AIDS Res Hum Retroviruses       Date:  2019-03       Impact factor: 2.205

Review 10.  Host-vaginal microbiota interactions in the pathogenesis of bacterial vaginosis.

Authors:  Christina A Muzny; Paweł Łaniewski; Jane R Schwebke; Melissa M Herbst-Kralovetz
Journal:  Curr Opin Infect Dis       Date:  2020-02       Impact factor: 4.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.